Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

Last month, NMD4C hosted its 2025 Annual Meeting in Ottawa

It was a full day of collaborative sessions, strategic discussions and networking that brought together clinicians, researchers, trainees, and partners from across Canada to advance neuromuscular research and care.

Meeting highlights included:

  • A recognition ceremony celebrating Early Career awardees and NM fellowship funding recipients
  • Flash talk presentations showcasing the work of early-career researchers
  • Networking breaks to foster collaboration and community building
  • Parallel group discussions to address key priorities in neuromuscular research and care:
    • Clinical Sessions explored:
      • Implementation strategies and awareness-building for new SBMA guidelines
      • Health administrative data linkage for SBMA, OPMD, SMA, and DMD with the CNDR
      • Barriers to implementing MRI and ultrasound into clinical practice
      • Planning for gene therapy in Canada
      • Development of combination treatment guidelines for SMA
      • Establishing and integrating DM1 outcome measures with CNDR datasets
    • Cross-disciplinary and Basic Science Sessions focused on:
      • Collaborative grant design and funding pathway exploration
      • Academic retention and postdoc-to-PI transition support
      • Enhancing access to shared resources and fostering preclinical-clinical collaborations
      • Synthesizing insights to prioritize next steps for cross-disciplinary initiatives

We extend our sincere thanks to our funders — Muscular Dystrophy Canada (MDC) and the Canadian Institutes of Health Research (CIHR) — and to all members, discussion leads, and partners who contributed to the success of this event.

Together, we are strengthening Canada’s neuromuscular research and care community.

We look forward to hosting our 2026 Annual Meeting just ahead of the WCNMC 2026 in Calgary on September 25, 2026!

 

See snapshots of the annual meeting in Our Gallery

2025 NMD4C ANNUAL MEETING

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.